Anti dose
lives of many could be at stake, with pharmaceutical giants shying away from the development of new antibiotics. Prominent experts have expressed this concern at the much-acclaimed 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, organised from September 14-17, 2003, in Chicago, usa. They allege that many companies, such as Roche and Eli Lilly, are just concentrating on the treatments of chronic illnesses. Signs of the retreat were quite clear during the meet. As compared to last year, there were 10 per cent fewer presentations pertaining to new drugs; there was even a slump in the number of the industry's representatives.
The change is quite untimely
Related Content
- Action plan for vulture conservation in India, 2020‐2025
- Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
- Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
- 100 Mewat children taken ill after having anti-malaria drug
- Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
- Use of Fixed Dose Combination (FDC) drugs in India: Central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), Metformin, or psychotropic drugs